Vasoactive substances: Nitric oxide and endothelial dysfunction in atherosclerosis

Vascular Pharmacology

Volumn 38, Issue 5, 2002, Pages 259-269

  Russo, Guilia ^a   Leopold, Jane A ^b   Loscalzo, Joseph ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Endothelium; Nitric oxide; Thrombosis

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; ACETYLCHOLINE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARGININE; ESTRADIOL; ESTROGEN; GLUCAGON; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NITROSO DERIVATIVE; ORGANIC NITRATE; REACTIVE OXYGEN METABOLITE; S NITROSOALBUMIN; S NITROSOTHIOL; SPERMINE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ARTERY INJURY; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; BIOSYNTHESIS; BRACHIAL ARTERY; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPORT; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STABILITY; DRUG TOLERANCE; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMORAL ARTERY; GENE THERAPY; HEART PROTECTION; HEMODYNAMICS; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATORY CELL; INTRAVASCULAR ULTRASOUND; ISCHEMIA; LEUKOCYTE ADHERENCE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; SHEAR STRESS; SIDE EFFECT; SUBSTITUTION THERAPY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASODILATOR AGENTS;

EID: 0036590626     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00250-1     Document Type: Article

References (101)

1. Adams M.R., Kinlay S., Blake G.J., Orford J.L., Ganz P., Selwyn A.P. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes. Annu. Rev. Med. 51:2000;149-167.
2. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., Lieberman E.H., Ganz P., Creager M.A., Yeung A.C., Selwyn A.P. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26:1995;1235-1241.
3. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271:1996;C1424-C1437.
4. Best L.C., Martin T.J., Russell R.G., Preston F.E. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature. 267:1977;850-852.
5. Bode-Boger S.M., Boger R.H., Kienke S., Junker W., Frolich J.C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun. 219:1996;598-603.
6. Bodzenta-Lukaszyk A., Gabryelewicz A., Lukaszyk A., Bielawiec M., Konturek J.W., Domschke W. Nitric oxide synthase inhibition and platelet function. Thromb. Res. 75:1994;667-672.
7. Boger R.H., Bode-Boger S.M., Mugge A., Kienke S., Brandes R., Dwenger A., Frolich J.C. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284.
8. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., Cooke J.P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 98:1998;1842-1847.
9. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler., Thromb., Vasc. Biol. 20:2000;1557-1564.
10. Buergler J.M., Tio F.O., Schulz D.G., Khan M.M., Mazur W., French B.A., Raizner A.E., Ali N.M. Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. Coron. Artery Dis. 11:2000;351-357.
11. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:2000;840-844.
12. Candipan R.C., Wang B.Y., Buitrago R., Tsao P.S., Cooke J.P. Regression or progression. Dependency on vascular nitric oxide. Arterioscler., Thromb., Vasc. Biol. 16:1996;44-50.
13. Cardillo C., Kilcoyne C.M., Cannon R.O. III, Quyyumi A.A., Panza J.A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 30:1997;57-63.
14. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
15. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561.
16. Clarkson P., Celermajer D.S., Donald A.E., Sampson M., Sorensen K.E., Adams M., Yue D.K., Betteridge D.J., Deanfield J.E. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 28:1996;573-579.
17. Cohen R.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cylic GMP. Circulation. 92:1995;3337-3349.
18. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler., Thromb., Vasc. Biol. 20:2000;2032-2037.
19. Cooke J.P., Andon N.A., Girerd X.J., Hirsch A.T., Creager M.A. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation. 83:1991;1057-1062.
20. Creager M.A., Cooke J.P., Mendelsohn M.E., Gallagher S.J., Coleman S.M., Loscalzo J., Dzau V.J. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86:1990;228-234.
21. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A. Jr., Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:1995;60-68.
22. De Keulenaer G.W., Alexander R.W., Ushio-Fukai M., Ishizaka N., Griendling K.K. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem. J. 329:1998;653-657.
23. Diodati J.G., Quyyumi A.A., Hussain N., Keefer L.K. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect. Thromb. Haemostasis. 70:1993;654-658.
24. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550.
25. Eberhardt R.T., Loscalzo J. Loscalzo J., Vita J.A. Nitric Oxide and the Cardiovascular System. vol. 4:2000;273-295 Humana Press, Towata, NJ.
26. Esmon C.T., Esmon N.L., Harris K.W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J. Biol. Chem. 257:1982;7944-7947.
27. Esmon N.L., Owen W.G., Esmon C.T. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem. 257:1982;859-864.
28. Fishman A.P. Endothelium: a distributed organ of diverse capabilities. Ann. N.Y. Acad. Sci. 401:1982;1-8.
29. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler. Thromb. 13:1993;1327-1333.
30. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:1999;597-601.
31. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
32. Gerhard M., Walsh B.W., Tawakol A., Haley E.A., Creager S.J., Seely E.W., Ganz P., Creager M.A. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 98:1998;1158-1163.
33. Gilligan D.M., Panza J.A., Kilcoyne C.M., Waclawiw M.A., Casino P.R., Quyyumi A.A. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation. 90:1994;2853-2858.
34. Girerd X.J., Hirsch A.T., Cooke J.P., Dzau V.J., Creager M.A. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ. Res. 67:1990;1301-1308.
35. Gooch K.J., Dangler C.A., Frangos J.A. Exogenous, basal, and flow-induced nitric oxide production and endothelial cell proliferation. J. Cell. Physiol. 171:1997;252-258.
36. Griendling K.K., Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J. Lab. Clin. Med. 132:1998;9-15.
37. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1994;1141-1148.
38. Guetta V., Quyyumi A.A., Prasad A., Panza J.A., Waclawiw M., Cannon R.O. III The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation. 96:1997;2795-2801.
39. Halliwell B., Gutteridge J.M. Lipid peroxidation in brain homogenates: the role of iron and hydroxyl radicals. J. Neurochem. 69:1997;1330-1331.
40. Higashi Y., Oshima T., Ono N., Hiraga H., Yoshimura M., Watanabe M., Matsuura H., Kambe M., Kajiyama G. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J. Clin. Endocrinol. Metab. 80:1995;2198-2202.
41. Hishikawa K., Luscher T.F. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation. 96:1997;3610-3616.
42. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84:1987;9265-9269.
43. Ignarro L.J., Buga G.M., Wei L.H., Bauer P.M., Wu G., del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 98:2001;4202-4208.
44. Ignarro L.J., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. 90:2002;21-28.
45. Jeserich M., Munzel T., Just H., Drexler H. Reduced plasma L-arginine in hypercholesterolaemia. Lancet. 339:1992;561.
46. Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., Luscher T.F. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
47. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
48. Kang S.S., Wong P.W., Glickman P.B., MacLeod C.M., Jaffe I.A. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment. J. Clin. Pharmacol. 26:1986;712-715.
49. Kanner J., Harel S., Granit R. Nitric oxide as an antioxidant. Arch. Biochem. Biophys. 289:1991;130-136.
50. Kifor I., Dzau V.J. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ. Res. 60:1987;422-428.
51. Lefer A.M., Ma X.L. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery. Arterioscler. Thromb. 13:1993;771-776.
52. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 49:2001;281-287.
53. Lefroy D.C., Crake T., Uren N.G., Davies G.J., Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation. 88:1993;43-54.
54. Leopold J.A., Loscalzo J. New developments in nitrosovasodilator therapy. Vasc. Med. 2:1997;190-202.
55. Leopold J., Loscalzo J. Loscalzo J., V. J.A. Nitric Oxide and the Cardiovascular System. vol. 4:2000;411-429 Humana Press, Towata, NJ.
56. Leopold J.A., Loscalzo J. Clinical importance of understanding vascular biology. Cardiol. Rev. 8:2000;115-123.
57. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 270:1995;319-324.
58. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P., Yeung A.C., Creager M.A. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121:1994;936-941.
59. Lieberman E.H., Gerhard M.D., Uehata A., Selwyn A.P., Ganz P., Yeung A.C., Creager M.A. Flow-induced vasodilation of the human brachial artery is impaired in patients 40 years of age with coronary artery disease. Am. J. Cardiol. 78:1996;1210-1214.
60. Lloyd-Jones D.M., Bloch K.D. The vascular biology of nitric oxide and its role in atherogenesis. Annu. Rev. Med. 47:1996;365-375.
61. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88:2001;756-762.
62. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1986;1046-1051.
63. Maalej N., Albrecht R., Loscalzo J., Folts J.D. The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces. J. Am. Coll. Cardiol. 33:1999;1408-1414.
64. Maier W.C.F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M., Meier B., Luscher T.F. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 35(2):2000;173-178.
65. Makrides S., Ryan U. Loscalzo J., Schafer A. Thrombosis and Hemorrhage. 1998;295-306 William and Wilkins, Baltimore.
66. Marks D.S., Vita J.A., Folts J.D., Keaney J.F. Jr., Welch G.N., Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J. Clin. Invest. 96:1995;2630-2638.
67. McLenachan J.M., Williams J.K., Fish R.D., Ganz P., Selwyn A.P. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 84:1991;1273-1278.
68. Meredith I.T., Anderson T.J., Uehata A., Yeung A.C., Selwyn A.P., Ganz P. Role of endothelium in ischemic coronary syndromes. Am. J. Cardiol. 72:1993;27C-31C. Discussion 31C-32C.
69. Morley D., Keefer L.K. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J. Cardiovasc. Pharmacol. 22:1993;S3-S9.
70. Moro M.A., Darley-Usmar V.M., Lizasoain I., Su Y., Knowles R.G., Radomski M.W., Moncada S. The formation of nitric oxide donors from peroxynitrite. Br. J. Pharmacol. 116:1995;1999-2004.
71. Murohara T., Witzenbichler B., Spyridopoulos I., Asahara T., Ding B., Sullivan A., Losordo D.W., Isner J.M. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler., Thromb., Vasc. Biol. 19:1999;1156-1161.
72. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA. 88:1991;10045-10048.
73. Newby A.C., George S.J. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr. Opin. Cardiol. 11:1996;574-582.
74. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
75. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
76. Rossoni G., Manfredi B., Colonna V.D., Bernareggi M., Berti F. The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. J. Pharmacol. Exp. Ther. 297:2001;380-387.
77. Sarkar R., Meinberg E.G., Stanley J.C., Gordon D., Webb R.C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ. Res. 78:1996;225-230.
78. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
79. Sinnaeve P., Chiche J.D., Nong Z., Varenne O., Van Pelt N., Gillijns H., Collen D., Bloch K.D., Janssens S. Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects. Circ. Res. 88:2001;103-109.
80. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 84:1991;1420-1425.
81. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99:1997;41-46.
82. Sullivan J.M., Vander Zwaag R., Hughes J.P., Maddock V., Kroetz F.W., Ramanathan K.B., Mirvis D.M. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch. Intern. Med. 150:1990;2557-2562.
83. Synek P., Rysanek K., Spankova H., Mlejnkova M. The effect of ethanol and nitroglycerin on platelet aggregation. Act. Nerv. Super. (Praha). 12:1970;77-78.
84. Szczeklik A., Musial J., Undas A., Swadzba J., Gora P.F., Piwowarska W., Duplaga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler., Thromb., Vasc. Biol. 16:1996;948-954.
85. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121.
86. Tousoulis D., Davies G., Lefroy D.C., Haider A.W., Crake T. Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: evidence for localised endothelial dysfunction. Heart. 75:1996;261-266.
87. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487.
88. van der Vliet A., Hoen P.A., Wong P.S., Bast A., Cross C.E. Formation of S-nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide. J. Biol. Chem. 273:1998;30255-30262.
89. Varenne O., Pislaru S., Gillijns H., Van Pelt N., Gerard R.D., Zoldhelyi P., Van de Werf F., Collen D., Janssens S.P. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 98:1998;919-926.
90. Varenne O., Sinnaeve P., Gillijns H., Iung B., Laurysens V., Meurrens K., Bout B., Valerio D., Collen D., Janssens S.P., Gerard R.D. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum. Gene. Ther. 11:2000;1329-1339.
91. Verbeuren T.J., Coene M.C., Jordaens F.H., Van Hove C.E., Zonnekeyn L.L., Herman A.G. Effect of hypercholesterolemia on vascular reactivity in the rabbit: II. Influence of treatment with dipyridamole on endothelium-dependent and endothelium-independent responses in isolated aortas of control and hypercholesterolemic rabbits. Circ. Res. 59:1986;496-504.
92. Vita J.A., Keaney J.F. Jr. Lanzer P., Lipton M. Diagnostics Vascular Diseases: Principals and Technology. 1996;249-259 Springer, Berlin.
93. Vita J.A., Treasure C.B., Nabel E.G., McLenachan J.M., Fish R.D., Yeung A.C., Vekshtein V.I., Selwyn A.P., Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
94. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev. Physiol. Biochem. Pharmacol. 113:1989;41-88.
95. Weis J.R., Pitas R.E., Wilson B.D., Rodgers G.M. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5:1991;2459-2465.
96. Welch G., Loscalzo J. Nitric oxide and the cardiovascular system. J. Cardiovasc. Surg. 9:1994;361-371.
97. Werns S.W., Walton J.A., Hsia H.H., Nabel E.G., Sanz M.L., Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 79:1989;287-291.
98. Wever R.M., Luscher T.F., Cosentino F., Rabelink T.J. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 97:1998;108-112.
99. Weyrich A.S., Ma X.L., Buerke M., Murohara T., Armstead V.E., Lefer A.M., Nicolas J.M., Thomas A.P., Lefer D.J., Vinten-Johansen J. Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated cardiac muscle. Circ. Res. 75:1994;692-700.
100. Yin Z.L., Dusting G.J. A nitric oxide donor (spermine-NONOate) prevents the formation of neointima in rabbit carotid artery. Clin. Exp. Pharmacol. Physiol. 24:1997;436-438.
101. Zeiher A.M., Drexler H., Wollschlager H., Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation. 84:1991;1984-1992.